Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.
2 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 8
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Agilent is discussing revenue growth due to stable demand and biopharma recovery, while also noting how tariff concerns are impacting order trends in China.Sub-event
- Slowdown in pharmaceutical spending in China is impacting companies like Novartis, with potential effects from US generic market entries.Sub-event
- Bruker and Humana are facing soft demand from academic institutions and a slowdown in the biopharma market.Sub-event
- Richard Tobin cited positive margin mix from growth platforms for BioPharma.Sub-event
- Penumbra is facing growth impacts due to uncertainties regarding FDA review timelines and revenue decline in China.Sub-event
- Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.Sub-event
Tariffs and China's slow stimulus are causing caution and delaying biopharma investments.1 source
Biopharma market faces challenging demand but shows signs of recovery in drug discovery.1 source
Keep exploring
The entities involved
-
China
cultural region, ancient civilization, and nation in East Asia; mostly refers to the People's Republic of China in political situation and rarely refers to the Republic of China
-
BioPharma
company in Jílové u Prahy, Czech Republic
-
Bruker
American company
Related events
- Chinese tariffs have lowered Canadian earnings, while biofuel demand is driving crop usage.
- Morgan Stanley highlighted guidance regarding Nvidia's sales, noting that market uncertainty surrounding China impacts the company's outlook.
- Trump threatens tariffs on China to reshore drug production, citing IP theft fears and seeking to protect commercial shipping interests.
- An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.
Coverage
Newest first; wire copies grouped- StockStoryBRKR Q2 Deep Dive: Funding and Tariff Headwinds Drive Guidance Cuts, Cost Actions Accelerate Scientific instrument company Bruker (NASDAQ:BRKR). missed Wall Street’s revenue expectations in Q2 CY2025
- Business WireBruker Reports Second Quarter 2025 Financial Results Q2 2025 revenues of $797.4 million, down 0.4% year-over-year (yoy); organic revenue down 7.0%, and constant-exchange rate (CER) revenue down 3.3%